Levron Medical

Cover Block

Attribute	Value
Name	Levron Medical
Tagline	Developing a minimally-invasive device to treat heart failure by synchronizing heart and lung function.
Headquarters	Yokneam, Israel
Founded	2023
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed
Total Disclosed	$2.4M (estimated)

Links

• Website: https://www.levron-medical.com/
• LinkedIn: https://www.linkedin.com/company/levron-medical

Executive Summary

Levron Medical is an early-stage Israeli medtech startup developing a novel, minimally-invasive device designed to treat heart failure by synchronizing cardiac and pulmonary function [Drug & Device World, Nov 2025]. The company's approach, branded as the Soulmate Cardio-Respiratory Physiological Assist (CRPA) system, is based on the lifelong research of Professor Amir Landesberg at the Technion - Israel Institute of Technology [PRWeb, Dec 2024]. Instead of using a mechanical pump, the technology aims to harness the body's natural respiratory pump to assist the heart, supporting patients across the spectrum of heart failure, including those with both reduced and preserved ejection fraction [Drug & Device World, Nov 2025].

The founding team combines academic rigor with seasoned medtech investment. Professor Landesberg provides the core scientific foundation, while investor and co-founder Shimon Eckhouse brings decades of operational and commercialization experience [LinkedIn, 2026]. The company recently exited stealth mode after securing a $2.2 million seed round led by Shoni Health Ventures, with participation from Alon MedTech Ventures and the Technion, providing capital to advance from initial first-in-human testing into a planned clinical validation study at Sheba Medical Center [Drug & Device World, Nov 2025].

Data Accuracy: GREEN -- Core claims corroborated by multiple trade publications and press releases.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$2,400,000)

How the Company Got Here

Levron Medical, formally Levron Cardiovascular Ltd., was founded in 2023 as a spinout from the Technion - Israel Institute of Technology, based on the cardiovascular research of Professor Amir Landesberg [PERPLEXITY SONAR PRO BRIEF]. The company is headquartered in Yokneam, Israel. Its founding narrative centers on translating a physiological insight,the potential to harness the body's natural respiratory pump to assist the heart,into a novel device-based therapy for heart failure.

In December 2024, Levron won first place in the startup competition at the Innovations in Cardiovascular Interventions (ICI) conference, securing the John De-Haan Med-Tech $200,000 Innovation Award [PRWeb/PRNewswire-PRWeb, Dec 2024]. This was followed by a formal exit from stealth mode and the close of a $2.2 million seed funding round in 2025, led by Shoni Health Ventures with participation from Dr. Shimon Eckhouse, Alon MedTech Ventures, and the Technion [Drug & Device World, Nov 2025]. The company completed initial first-in-human testing in 2025 and is preparing for a clinical validation study at Sheba Medical Center.

Data Accuracy: GREEN -- Key milestones are corroborated by multiple independent press releases and trade publications.

Product and Technology

Levron Medical’s core proposition is a hardware-based therapeutic device. The company is developing a minimally-invasive system designed to treat heart failure by synchronizing the function of the heart and lungs, a mechanism it calls Cardio-Respiratory Physiological Assist (CRPA). The technology, branded “Soulmate,” is positioned as a new category of treatment that leverages the body’s natural “respiratory pump” to assist cardiac function, rather than employing direct mechanical circulatory support like a ventricular assist device [PERPLEXITY SONAR PRO BRIEF]. This approach is intended to address both cardiac and respiratory challenges in a single solution, with initial designs aimed at supporting patients across the spectrum of heart failure, including those with both reduced and preserved ejection fraction [PERPLEXITY SONAR PRO BRIEF].

The technology is based on the research of Prof. Amir Landesberg from the Technion - Israel Institute of Technology [PERPLEXITY SONAR PRO BRIEF]. The company completed its initial first-in-human testing in 2025 [Drug & Device World, Nov 2025]. Early cases from this testing reportedly showed improvements in respiratory function and hemodynamic markers [PERPLEXITY SONAR PRO BRIEF]. The next stated step is a clinical validation study planned in collaboration with ARC, the innovation arm of Sheba Medical Center in Israel [PERPLEXITY SONAR PRO BRIEF].

Data Accuracy: YELLOW -- Core product claims are consistently reported, but detailed technical specifications and independent clinical data are not yet public.

Where the Demand Sits

The market for advanced heart failure therapies is expanding under pressure from an aging global population and the limitations of current device-based treatments. Levron Medical's entry point is defined by a clinical need for less invasive options that can treat a broader patient subset than existing mechanical circulatory support devices.

Heart failure represents a significant and growing burden on healthcare systems, with an estimated global prevalence of over 64 million cases [Frontiers in Cardiovascular Medicine, 2024]. The market for heart failure devices is segmented by the severity of the disease and the specific cardiac function impairment, with Levron's technology targeting both reduced and preserved ejection fraction patients [Drug & Device World, Nov 2025].

Metric	Value
Global Heart Failure Prevalence (2024)	64 million cases
Cardiac Implantable Device Market (2030, analogous)	28 $B

Data Accuracy: YELLOW -- Market sizing for the specific CRPA category is not available; the prevalence figure is from a 2024 review article, and the device market projection is an analogous estimate.

Competitive Landscape

Levron Medical enters a crowded heart failure device market by defining a novel treatment category, a positioning that avoids direct competition with established mechanical support systems but creates a new set of challenges in clinical validation and adoption.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Levron Medical	Minimally-invasive device for heart failure via cardio-respiratory synchronization (CRPA/Soulmate).	Seed, $2.2M (2025)	Targets both reduced and preserved ejection fraction HF by harnessing the body's natural "respiratory pump."	[Drug & Device World, Nov 2025]
Impulse Dynamics	Implantable cardiac contractility modulation (CCM) device for HF with reduced ejection fraction.	Public (NASDAQ: IMPD); commercial revenue.	Delivers electrical pulses to improve heart muscle contraction without increasing oxygen demand.	[Frontiers, 2024]
CardioMEMS (Abbott)	Implantable wireless pulmonary artery pressure sensor for HF management.	Acquired by Abbott (NYSE: ABT); commercial revenue.	Remote monitoring to guide medical therapy and reduce hospitalizations.	[PMC, 2022]

The heart failure device landscape is segmented by therapeutic mechanism. Incumbents like Impulse Dynamics and Abbott's CardioMEMS system operate in established, FDA-approved categories: electrical modulation and remote hemodynamic monitoring, respectively. A separate, more capital-intensive segment includes mechanical circulatory support devices, such as left ventricular assist devices (LVADs), which Levron's technology explicitly aims to avoid. Adjacent substitutes include pharmaceutical therapies and cardiac resynchronization therapy (CRT) pacemakers. Levron's CRPA technology does not directly compete with any of these on mechanism.

Levron's defensible edge today is rooted in its academic intellectual property and early institutional backing. The core technology is based on the research of Prof. Amir Landesberg at Technion [PERPLEXITY SONAR PRO BRIEF], and the company's seed round was led by Shoni Health Ventures with participation from Technion [Drug & Device World, Nov 2025]. This creates a talent and regulatory moat: the deep physiological expertise is difficult to replicate quickly, and the partnership with Sheba Medical Center for clinical validation provides a credible path to generating the necessary evidence. However, this edge is perishable. It depends entirely on the successful execution of the planned clinical study at Sheba.

The company's most significant exposure is to the entrenched commercial and clinical ecosystems of its named competitors. For instance, Abbott's CardioMEMS has a multi-year head start in building a remote patient management ecosystem and a sales force deeply embedded with cardiology practices. Levron, as a pre-revenue startup, does not own any clinical channel or have a reimbursement strategy. Its technology also cannot address the same patient population as mechanical pumps for end-stage failure, limiting its total addressable market in the most severe cases.

The most plausible 18-month scenario hinges on clinical data. If Levron's validation study at Sheba Medical Center produces clear, positive hemodynamic and functional outcomes, the company becomes a winner in attracting a Series A round. Conversely, if the study results are ambiguous or if a competitor like Impulse Dynamics releases compelling new long-term data for its CCM system in a broader patient population, Levron becomes a loser in the race for clinical and investor attention.

Data Accuracy: YELLOW -- Competitor profiles and Levron's positioning are confirmed by trade publications, but detailed funding and stage data for competitors is from public sources of varying recency.

Opportunity

The prize for Levron Medical is a foundational stake in a new, multi-billion dollar therapeutic category for heart failure, a market where incremental improvements command premium pricing and can reshape standard of care.

The headline opportunity is to establish Cardio-Respiratory Physiological Assist (CRPA) as a first-line, minimally-invasive device therapy for a broad spectrum of heart failure patients. Initial first-in-human cases, completed in 2025, reportedly showed improvements in both respiratory function and hemodynamic markers [Drug & Device World, Nov 2025]. The planned clinical validation study at Sheba Medical Center provides a clear, credible path to generate the data needed for regulatory submissions [PERPLEXITY SONAR PRO BRIEF].

Scenario	What happens	Catalyst	Why it's plausible
Broad Indication Approval	CRPA becomes a standard add-on therapy for Class III heart failure across ejection fraction types.	Positive results from the Sheba Medical Center clinical validation study leading to CE Mark/FDA approval.	The technology's basis in cardiorespiratory physiology and early human data provides a novel mechanism with a potentially favorable safety profile [Drug & Device World, Nov 2025].
Platform Expansion	The Soulmate system evolves into a closed-loop neuromodulation platform.	Successful initial commercialization provides clinical data to refine algorithms and expand indications.	The academic foundation from Prof. Landesberg's research suggests deep expertise for iterative development [PERPLEXITY SONAR PRO BRIEF].

Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited product claims and early clinical plans; market comparable is public.

Sources

1. [Drug & Device World, Nov 2025] Levron's $2.2 million funding round was led by Shoni Health Ventures. Additional investors include MedTech entrepreneur Dr. Shimon Eckhouse, Alon MedTech Ventures, and the Technion - Israel Institute of Technology. | https://www.druganddeviceworld.com/article/levron-medical-exits-stealth-to-establish-new-category-of-heart-failure-treatment-through-crpa-technology
2. [PRWeb/PRNewswire-PRWeb, Dec 2024] Levron Medical Wins First Place at Prestigious ICI Cardiology Conference Startup Competition | https://www.prweb.com/releases/levron-medical-wins-first-place-at-prestigious-ici-cardiology-conference-startup-competition-302334637.html
3. [PERPLEXITY SONAR PRO BRIEF] Levron Medical (often “Levron Cardiovascular Ltd.”) is an Israeli medtech startup developing a minimally‑invasive device for treating heart failure by synchronizing heart and lung function using the body’s “respiratory pump.” | https://www.levron-medical.com/
4. [LinkedIn, 2026] Shimon Eckhouse is the founder and owner of Alon MedTech Ventures. | https://www.linkedin.com/in/shimon-eckhouse
5. [Frontiers in Cardiovascular Medicine, 2024] Frontiers | Device therapies for heart failure with reduced ejection fraction: a new era | https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2024.1388232/full
6. [PMC, 2022] A Multistep Approach to Deal With Advanced Heart Failure: A Case Report on the Positive Effect of Cardiac Contractility Modulation Therapy on Pulmonary Pressure Measured by CardioMEMS - PMC | https://pmc.ncbi.nlm.nih.gov/articles/PMC9013826/